The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
CNS Demyelination with TNF-α Blockers
Open accessAbstract
Tumor necrosis factor-α (TNF-α) blockers are a popular therapeutic choice in a number of inflammatory diseases. Thus far, five TNF- α blockers have been approved for clinical use (etanercept, infliximab, adalimumab, golimumab. and certolizumab). Despite being considered relatively safe, serious side effects associated with immune suppression have been reported, including central and peripheral nervous system (CNS) demyelinating disorders. It is still elusive whether these events are mere coincidence or a side effect of anti-TNF-α use. In this paper, we review the published case reports of CNS demyelination associated with anti-TNF-α therapy and present the follow-up of our 4 previously reported patients who developed neurologic symptoms suggestive of CNS demyelination after having received anti-TNF-α treatment. We also discuss the possible role of TNF-α blockers in demyelination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Kalliolias, G. D., & Ivashkiv, L. B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.169 · Cited by 1,387
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,017
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012
Macrophage defense mechanisms against intracellular bacteria
Weiss, G., & Schaible, U. E. (2015) · Immunological Reviews · doi:10.1111/imr.12266 · Cited by 989
Transmembrane TNF- : structure, function and interaction with anti-TNF agents
Horiuchi, T., Mitoma, H., Harashima, S.-I., Tsukamoto, H., & Shimoda, T. (2010) · Rheumatology · doi:10.1093/rheumatology/keq031 · Cited by 864
Sharief, M. K., & Hentges, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250704 · Cited by 809
Tumor necrosis factor identified in multiple sclerosis brain.
Hofman, F. M., Hinton, D. R., Johnson, K., & Merrill, J. E. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.2.607 · Cited by 801
Sedger, L. M., & McDermott, M. F. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.07.016 · Cited by 771
Cited by
Amoruso, A., Blonda, M., Gironi, M., Grasso, R., Di Francescantonio, V., Scaroni, F., Furlan, R., Verderio, C., & Avolio, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-63282-3 · Cited by 46
Role of Imaging Modalities and N -Acetylcysteine Treatment in Sepsis-Associated Encephalopathy
Zhong, Y., Guan, J., Ma, Y., Xu, M., Cheng, Y., Xu, L., Lin, Y., Zhang, X., & Wu, R. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00180 · Cited by 17
Metadata
- Authors
- Kemanetzoglou, E., & Andreadou, E.
- Venue
- Current Neurology and Neuroscience Reports
- Published
- 2017-03-21
- Volume
- 17
- Issue
- 4
- Pages
- 36-36
- ISSN
- 1528-4042 (ISSN-L)
- 1534-6293
- OpenAlex
- W2602416590
- Cited by
- 319
- References
- 74
- FWCI
- 19.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CNS Demyelination with TNF-α Blockers. https://app.cochat.ai/papers/10.1007/s11910-017-0742-1
- The paper
- Kemanetzoglou, E., & Andreadou, E. (2017). CNS Demyelination with TNF-α Blockers. Current Neurology and Neuroscience Reports. https://doi.org/10.1007/s11910-017-0742-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
